Endoscopic treatment of massive rectal bleeding following transrectal ultrasound-guided prostate biopsy

Pacios, Enrique; Esteban, José M.; Breton, Maria Luisa; Alonso, M. García; Sicilia-Urbán, Juan Jose; Fidalgo, M.

doi:10.1080/00365590601116832

Cited by 12 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…90 Colonoscopy with injection of epinephrine and polidocanol or use of sclerotherapeutic agents, angiography with embolization, 91 transrectal exploration, and suturing are alternative means of stopping rectal bleeding. 92,93 Hematuria may be managed similarly with bed rest, volume resuscitation and transfusion. Cystoscopy or anoscopy with coagulation of bleeding points may be used in more severe cases.…”

Section: Complicationsmentioning

confidence: 99%

Optimization of Prostate Biopsy

Bjurlin

Wysock

Taneja

2014

Urologic Clinics of North America

View full text Add to dashboard Cite

Section: Complicationsmentioning

confidence: 99%

Optimization of Prostate Biopsy

Bjurlin

Wysock

Taneja

2014

Urologic Clinics of North America

View full text Add to dashboard Cite

“…Although rare, prostate biopsy can potentially have fatal outcome. A few cases (mainly case reports) of profuse potentially life‐threatening rectal haemorrhage have been reported in the literature; some have required different types of interventions but, to the best of our knowledge, there are no reported fatalities from rectal bleeding [5–14]. Fatal cases described in the literature (Table 1) were mainly caused by septicaemia; either anaerobic or as a result of Escherichia coli [3,15–23].…”

Section: Introductionmentioning

confidence: 99%

No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer

Carlsson

Holmberg²,

Moss

et al. 2010

BJU International

View full text Add to dashboard Cite

• Incidence rate ratios (RR) and statistical significance were evaluated using Poisson regression analyses, adjusting for age, total PSA level, screening centre and whether a biopsy indication was present, or whether a biopsy was actually performed or not. RESULTS• There was no statistically significant difference in cumulative 120-day other cause mortality between the two groups of men: 0.24% (95% CI, 0.17-0.34) for screening-positive men vs 0.24% (95% CI, 0.20-0.30) for screening-negative men ( P = 0.96). This implied no excess mortality for screening-positive men.• Screening-positive men who were not biopsied ( n = 1238) had a more than fourfold risk of other cause mortality during the first 120 days compared to screening-negative men: RR, 4.52 (95% CI, 2.63-7.74) ( P < 0.001), adjusted for age, whereas men who were actually biopsied ( n = 11 721) had half the risk: RR, 0.41 (95% CI, 0.23-0.73) ( P = 0.002), adjusted for age.• Only 14/31 (45%) of the screeningpositive men who died within 120 days were biopsied and none died as an obvious complication to the biopsy. CONCLUSION• Prostate biopsy is not associated with excess mortality and fatal complications appear to be very rare. PATIENTS AND METHODS• From three centres in the ERSPC (Finland, The Netherlands and Sweden) 50 194 screened men aged 50.2-78.4 years were prospectively followed. A cohort of 12 959 first-time screening-positive men (i.e. with biopsy indication) was compared with another cohort of 37 235 first-time screening-negative men.• Overall mortality rates (i.e. other cause than prostate cancer mortality) were calculated and the 120-day and 1-year cumulative mortality were calculated by the Kaplan-Meier method, with a log-rank test for statistical significance.

show abstract

“…The value at our center was 1.9%. Massive rectal bleeding could be controlled by rectal balloon tamponade, endoscopic adrenaline injection or sclerotherapy, or direct vessel clipping [22–25]. Most fever patients could be cured by oral antibiotics.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of prostate cancer detection rate (PCDR) in Chinese Han population under different prostate biopsy methods

et al. 2017

View full text Add to dashboard Cite

We analyzed the improvement of prostate cancer detection rate (PCDR) in Chinese Han population and summarized the characteristics of prostate cancer (PCa) with the advancement of prostate biopsy technologies. From March 1999 to March 2015, 3762 patients underwent the systematic 6-, 8- or 13-core biopsy, guided by finger or transrectal ultrasound (TRUS) at our center. The PCDR under different PSA intervals and different biopsy methods were analyzed. The trends of PSA level, age and Gleason score of PCa patients were summarized. The PCDR of finger-guided 6- and 8-core biopsies were 30.8% (340/1103) and 36.7% (147/401) respectively. In 2258 patients with TRUS-guided 13-core biopsies, 992 (43.9%) were diagnosed as PCa, higher than that with finger-guided biopsies (43.9% vs. 32.4%, p < 0.001). The PCDR of prostate peripheral zone was higher than that of medial zone (37.5% vs. 31.4%, p < 0.001). Interestingly, the PCDR of extra 13th core was higher than the mean positive rate of other 12 cores (70.7% vs. 56.0%, p < 0.001). The systematic 13-core prostate biopsy guided by TRUS is safe, effective, and economic for PCa diagnosis in developing countries like China. The extra 13th core biopsy is beneficial to increase the PCDR.

show abstract

Endoscopic treatment of massive rectal bleeding following transrectal ultrasound-guided prostate biopsy

Cited by 12 publications

References 11 publications

Optimization of Prostate Biopsy

Optimization of Prostate Biopsy

No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer

Characteristics of prostate cancer detection rate (PCDR) in Chinese Han population under different prostate biopsy methods

Contact Info

Product

Resources

About